Recursion pharmaceuticals inc
RXRX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
RXRX 近期報酬表現
3.57%
Recursion pharmaceuticals inc
6.23%
同產業平均
1.02%
S&P500
與 RXRX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TWST | Twist bioscience corp | 3 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
ABSI | Absci corp | - | 3 分 | 2 分 | 1 分 | 1 分 | |
ADPT | Adaptive biotechnologies corp | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
DNA | Ginkgo bioworks holdings inc | 2 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
OMIC | Singular genomics systems inc | - | 2 分 | 2 分 | 1 分 | 1 分 |
- TWST Twist bioscience corp價值 3 分趨勢 3 分波段 2 分籌碼 2 分股利 1 分查看更多
RXRX 公司資訊
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.